Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance), a US-based cancer...
Pep Therapy, a biotechnology company developing peptides as targeted therapies for oncology, announces that its first-in-class drug candidate, PEP-010, successfully completed Good Laboratory Practice (GLP) toxicity study, moving towards its first-in-human clinical...
Studies represent work of more than 60 Dana-Farber Cancer Institute led research teams Three researchers are recipients of ASCO’s Special Awards, the Society’s highest honors Boston – Dana-Farber Cancer Institute researchers are presenting more than 70 research...
Tools4Patient, S.A., developer of tools to optimize and accelerate drug development programs, today announced it raised €4 million ($4.5 million) in an oversubscribed Series B equity financing round. New institutional investors include Innovation Fund and Sambrinvest....
In a National Institutes of Health-funded randomized controlled clinical trial, To Quit, MindSciences’ smoking cessation app, has shown a dose-dependent relationship between app use and reduction in cigarette smoking. The trial involved 67 subjects who received...
Presented at the World Advanced Therapies & Regenerative Medicine Congress & Expo 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune...
Email
Text